Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes

X
Trial Profile

A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plogosertib (Primary) ; Plogosertib (Primary)
  • Indications Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2024 Status changed from recruiting to discontinued.
    • 18 Dec 2023 According to a Cyclacel Pharmaceuticals media release, patients are being recruited at dose level 5. To date, 15 patients have been recruited at five dose escalation levels.
    • 22 Apr 2022 Planned End Date changed from 28 Feb 2021 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top